Thrivent Financial for Lutherans Has $345,000 Stake in Moderna, Inc. $MRNA

Thrivent Financial for Lutherans reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 85.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,341 shares of the company’s stock after selling 79,658 shares during the period. Thrivent Financial for Lutherans’ holdings in Moderna were worth $345,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Moderna by 3.2% in the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock valued at $1,150,743,000 after acquiring an additional 1,312,192 shares during the period. Geode Capital Management LLC raised its stake in Moderna by 19.1% in the 2nd quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock worth $244,458,000 after purchasing an additional 1,420,690 shares in the last quarter. Theleme Partners LLP boosted its holdings in Moderna by 8.6% in the 2nd quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock valued at $217,100,000 after purchasing an additional 626,420 shares during the period. Invesco Ltd. grew its position in shares of Moderna by 20.7% during the 2nd quarter. Invesco Ltd. now owns 7,101,032 shares of the company’s stock worth $195,917,000 after purchasing an additional 1,217,408 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Moderna during the 2nd quarter worth approximately $94,910,000. 75.33% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on MRNA shares. The Goldman Sachs Group lifted their price target on shares of Moderna from $36.00 to $41.00 and gave the company a “neutral” rating in a research report on Tuesday. TD Cowen reaffirmed a “hold” rating on shares of Moderna in a report on Thursday, January 29th. Evercore set a $35.00 target price on Moderna in a report on Tuesday. Bank of America decreased their price target on Moderna from $24.00 to $21.00 and set an “underperform” rating on the stock in a research report on Monday, November 10th. Finally, BMO Capital Markets raised shares of Moderna from a “market perform” rating to a “buy” rating in a research report on Monday, January 12th. Two equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Reduce” and an average target price of $31.47.

Moderna Price Performance

Shares of MRNA stock opened at $46.60 on Thursday. The business has a fifty day simple moving average of $38.21 and a 200 day simple moving average of $30.15. The company has a market cap of $18.21 billion, a P/E ratio of -6.41 and a beta of 1.32. The company has a quick ratio of 3.22, a current ratio of 3.29 and a debt-to-equity ratio of 0.07. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $55.20.

Moderna (NASDAQ:MRNA) last issued its earnings results on Friday, February 13th. The company reported ($2.11) EPS for the quarter, topping the consensus estimate of ($2.79) by $0.68. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The firm had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. During the same quarter in the previous year, the firm earned ($2.91) earnings per share. The business’s quarterly revenue was down 33.2% on a year-over-year basis. On average, sell-side analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA accepted Moderna’s revised application and will initiate review of mRNA-1010 with an Aug. 5, 2026 PDUFA date; Moderna proposed an age‑based approval pathway (full approval for adults 50–64, accelerated approval for 65+) which could speed rollout for the 2026–27 flu season. Read More.
• Positive Sentiment: Market reaction: multiple outlets report a share pop after the review decision, reflecting investor optimism about near‑term commercial upside if approved. Read More.
• Positive Sentiment: Clinical pipeline momentum: a mid‑stage trial of a combo flu/COVID mRNA vaccine showed robust immune responses and no safety signals — supportive for Moderna’s broader respiratory vaccine strategy. Read More.
• Positive Sentiment: European expansion: the European Commission granted marketing authorization for Moderna’s COVID vaccine mNEXSPIKE, strengthening its respiratory portfolio in Europe. Read More.
• Neutral Sentiment: Analyst view: Goldman Sachs raised its price target to $41 but kept a “neutral” rating — a modest positive to guidance but still implies limited near‑term upside per that shop. Read More.
• Neutral Sentiment: Regulatory uncertainty remains: the FDA’s earlier refusal and the public debate around it show there is still execution risk and potential delays until the Aug. decision. Read More.
• Negative Sentiment: Legal risk: a court recently rejected two Moderna defenses in its patent dispute with Arbutus, keeping intellectual‑property exposure and potential liabilities on the table. Read More.

Insider Activity

In other news, Director Noubar Afeyan sold 23,853 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total value of $703,186.44. Following the completion of the transaction, the director directly owned 3,924 shares in the company, valued at approximately $115,679.52. This represents a 85.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 10.90% of the company’s stock.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.